Citius (CTXR) May Be Among the Best Biopharma Value Plays Multiple near-term catalysts anticipated Good day everyone, We are continuing our coverage o...
FDA Approves Qwo (collagenase clostridium histolyticum-aaes) as the First Injectable Treatment for Cellulite
Article Link: FDA Approves Qwo (collagenase clostridium histolyticum-aaes) as the First Injectable Treatment for Cellulite DUBLIN, July 6...
FDA Approves Byfavo (remimazolam injection) for the Induction and Maintenance of Procedural Sedation
Article Link: FDA Approves Byfavo (remimazolam injection) for the Induction and Maintenance of Procedural Sedation Dublin, Ireland – 2 Ju...
Arcimoto (NASDAQ: FUV) Looking Very Strong here up Over 100% Since our Initial Report June 22nd, 2020
Arcimoto (NASDAQ: FUV) is Emerging as a Leader in the Electric Vehicle Revolution. Back log of $80M, Insider buying and Analyst coverage inside this c...
FDA Approves Rukobia (fostemsavir) for HIV in Adults with Few Treatment Options Available
Article Link: FDA Approves Rukobia (fostemsavir) for HIV in Adults with Few Treatment Options Available July 2, 2020 — ViiV Healthc...
FDA Approves Dojolvi (triheptanoin) for the Treatment of Long-Chain Fatty Acid Oxidation Disorders
Article Link: FDA Approves Dojolvi (triheptanoin) for the Treatment of Long-Chain Fatty Acid Oxidation Disorders NOVATO, Calif., June 30,...
Leading the Way in The Hot Electric Vehicle Sector, Arcimoto (NASDAQ: FUV)
"The move toward electric vehicles will continue at a rapid pace. The global Electric Vehicle Market Size was estimated at $162.34 Billion in 2019 and...
FDA Approves Bavencio as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Article Link: FDA Approves Bavencio as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma ...
FDA Approves Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) for HER2-Positive Breast Cancer
Article Link: FDA Approves Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) for HER2-Positive Breast Cancer South San Francisco, ...
FDA Approves Merck’s Keytruda (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
Article Link: FDA Approves Merck’s Keytruda (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorec...